Rise and shine, everyone, another busy day is on the way. The holiday season may be fast approaching but there is still work to be done. After all, the world continues to spin no matter how hard we try to slow it down. So please join us as we reach for another cup of stimulation — or grab a bottle of water, if you prefer — and get ready to embrace the familiar rituals. Meanwhile, here are a few items of interest to help you along. Have a wonderful day and, of course, do stay in touch.

Novartis (NVS) aims to give away 100 doses of its $2.1 million-per-patient Zolgensma for spinal muscular atrophy in 2020 in a program one patient group worried is a “health lottery” that could neglect some babies, Reuters says. The program would apply to countries where the medicine is not yet approved for the rare genetic disorder that affects only about 1 in 10,000 live births. But regulatory decisions in Europe and Japan have been delayed until 2020, curbing access that Novartis hopes to partially address where giveaways are allowed.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy